Reaction profile

The FDA adverse-event record for cachexia

101 FDA adverse-event reports reference cachexia (VeDDRA 1051). Plate codes and volume neighbourhood below; species, breeds, and drugs follow.

#1387 of 2,481
by report volume (all reactions)
101
reports citing this reaction
61.4%
death-coded share
Dog
most-affected species

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Cachexia has 101 reports now versus 99 in that prior snapshot: 2 more (2.0%).

Report change
+2
Death-coded reports
+1
Death-coded share
−0.2 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Cachexia changes

FDA AER · VeDDRA plate

Code 1051 VOL-LOW

VOL-LOW · DEATH-HOT · MID-PACK · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

  • VOL-LOW 101 reports
  • DEATH-HOT 61.4%
  • MID-PACK #1387/2481
  • PHOTO-FINISH Elevated mean corpusc…
  • SPECIES-DOG Dog · 57
  • DRUG-LEAD Trilostane · 11
  • DESK-WIDE 20 breeds
  • BOOK-FULL 8/8 fields

Nearest volume peer: Elevated mean corpuscular volume (MCV) (±0 reports)

Upper-third death-coded share drives the outcome stamps on this plate; volume band, corpus rank, and co-report peers follow. Not a clinical diagnosis.

Report-volume neighbourhood around Cachexia

Highest and lowest poles plus nearest volume peers, not a full 2,500-reaction corpus board reprint.

Vomiting · highest174348Cachexia · this reaction101Elevated mean corpusc… · near101Eructation · near101Idiopathic vestibular… · near101INEFFECTIVE, SARCOPTE… · near101Urinary tract neoplas… · low…10
FDA AER report volume · neighbourhood around Cachexia

Cachexia: high death-coded share in the FDA AER plate

Signature read: Cachexia's 61.4% death-coded share is among the highest in the openFDA reaction corpus. Report volume sits in the middle third of the reaction corpus. Death-coded share is upper-third: 62 of 101 reports (61.4% of named reports). Nearest volume peer: Elevated mean corpuscular volume (MCV) (±0 reports). Lead species Dog (57). Lead co-reported drug Trilostane (11).

Read these counts as reporting volume, not risk: per our methodology, A high death-coded share in FDA filings does not prove causation; co-reporting is voluntary temporal association only. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 57
Cat 32
Cattle 6
Sheep 2
Horse 2
Quail 1
Ferret 1

Breeds Most Affected

Domestic Shorthair 15
Crossbred Canine/dog 7
Domestic Mediumhair 5
Retriever - Labrador 5
Dachshund (unspecified) 4
Chihuahua 4
Cattle (other) 3
Terrier - Boston 3
Terrier - Yorkshire 3
Pit Bull 2

Associated Drugs

Trilostane 11
Spinosad 10
Maropitant Citrate 8
Enrofloxacin 7
Cefovecin 6
Robenacoxib 5
Prednisone 5
Clindamycin 4
Maropitant 4
Frunevetmab 4
Selamectin 3
Gamithromycin 3
Milbemycin Oxime + Spinosad 3
Furosemide 3
Vitamin B12 3
Famotidine 3
Cephalexin 3
Cefovecin Sodium 3
Dexamethasone 3
Metronidazole 3

Nationwide reactions with similar profiles

Two openFDA-derived peer sets for Cachexia, both floored at ≥50 reports so the neighborhoods stay in the advertised mass (the volume chart above is the unfloored photo-finish strip).

Similar death-coded share

Nearest other reactions by death-coded share (61.4% here), distinct from the volume row.

What to do with this reaction

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Cachexia (#1387 of 2,481 by report volume); death-coded 61.4%. PlainBreed reaction plate · death-coded share stamp 61.4% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →